HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

S66913

a nanomolar atrial-selective ion channel blocker that selectively inhibits potassium ion flux through the Kv1.5 ion channel

Also Known As:

XEN-D0103

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- S66913: 3

Experts

1.	Round, Patrick: 2 articles (04/2018 - 02/2016)
2.	Camm, A John: 1 article (01/2019)
3.	Dorian, Paul: 1 article (01/2019)
4.	Hohnloser, Stefan H: 1 article (01/2019)
5.	Kowey, Peter R: 1 article (01/2019)
6.	Maison-Blanche, Pierre: 1 article (01/2019)
7.	Ni, Yongbin: 1 article (01/2019)
8.	Sanders, Prashanthan: 1 article (01/2019)
9.	Tyl, Benoît: 1 article (01/2019)
10.	Vandzhura, Victoria: 1 article (01/2019)

Related Diseases

1.	Atrial Fibrillation 01/01/2019 - "A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation." 04/01/2018 - "A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy." 02/01/2016 - "The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation."
2.	Tachycardia (Tachyarrhythmias) 01/01/2019 - "S66913 had no significant effect on AFB or on AFB plus atrial tachycardia (AT) burden, at any dosage; nor on any secondary endpoints including the number and duration of AT or AF episodes, and symptoms. "